CTOs on the Move

Synthekine

www.synthekine.com

 
Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Synthekine raised $82M on 09/17/2020
Synthekine raised $107.5M on 06/10/2021

Similar Companies

AmerisourceBergen Drug Corporation

AmerisourceBergen Drug Corporation is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Broncus Technologies, Inc.

Broncus Medical, Inc. is a well-funded, commercial stage company based in San Jose, CA. The Company`s mission is to deliver navigation, diagnostic & therapeutic technologies to treat patients with lung disease. The Company has a comprehensive intellectual property portfolio with over 75 patents including those issued, licensed, and pending. Along with Broncus Medical`s focus on technological advancements, it is committed to providing outstanding value to patients, healthcare professionals, investors and employees.

Muse bio

Muse bio is transforming genome engineering by enabling, for the first time, high throughput massively-multiplexed CRISPR editing of proteins, pathways, and genomes. Through our powerful bioinformatics and novel molecular approach, ForgeCraft generates low-cost libraries of thousands of designer protein, pathway, or genome variants each with specifically defined, trackable mutations. This allows the impact of specific changes to be determined through rapid selection and high throughput screening allowing research timelines and costs to be reduced.

Verge Genomics

We are pioneering a better drug discovery process using systems biology to improve the lives of people with neurodegenerative disorders.

Axcella Health

Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella`s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella`s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.